Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H - Concepedia

Concepedia

Publication | Open Access

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

DOI Full Paper Access

79

Citations

31

References

2018

Year

Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Steven Powell, Liza C. Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia I. Jalal,

MedicineImmunologyTumor ImmunityKeynote-021 Cohorts DImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung Cancer

References

	Year	Citations

Page 1

Page 1